Nymox Pharmaceutical Corporation (NYMX): Price and Financial Metrics


Nymox Pharmaceutical Corporation (NYMX): $1.26

0.01 (+0.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NYMX Stock Summary

  • With a price/sales ratio of 19,802.13, Nymox Pharmaceutical Corp has a higher such ratio than 99.91% of stocks in our set.
  • With a year-over-year growth in debt of 189.8%, Nymox Pharmaceutical Corp's debt growth rate surpasses 94.24% of about US stocks.
  • Revenue growth over the past 12 months for Nymox Pharmaceutical Corp comes in at -97.77%, a number that bests only 0.87% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to NYMX, based on their financial statements, market capitalization, and price volatility, are URG, CALT, MRSN, FSR, and EQS.
  • NYMX's SEC filings can be seen here. And to visit Nymox Pharmaceutical Corp's official web site, go to www.nymox.com.

NYMX Valuation Summary

  • In comparison to the median Healthcare stock, NYMX's price/earnings ratio is 138.9% lower, now standing at -14.2.
  • Over the past 243 months, NYMX's EV/EBIT ratio has gone up 8.9.
  • NYMX's price/sales ratio has moved up 32812.5 over the prior 243 months.

Below are key valuation metrics over time for NYMX.

Stock Date P/S P/B P/E EV/EBIT
NYMX 2021-08-31 33220 77.4 -14.2 -13.9
NYMX 2021-08-30 33680 78.5 -14.3 -14.1
NYMX 2021-08-27 34140 79.6 -14.5 -14.3
NYMX 2021-08-26 33220 77.4 -14.2 -13.9
NYMX 2021-08-25 33520 78.1 -14.3 -14.1
NYMX 2021-08-24 32120 74.9 -13.7 -13.5

NYMX Growth Metrics

    The 5 year cash and equivalents growth rate now stands at 261.2%.
  • Its 4 year revenue growth rate is now at -58.88%.
  • Its 3 year cash and equivalents growth rate is now at 1258.76%.
NYMX's revenue has moved down $218,846 over the prior 67 months.

The table below shows NYMX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 0 -9.255 -11.754
2021-06-30 0 -10.275 -12.612
2021-03-31 0 -10.537 -11.562
2020-12-31 0.005 -10.037 -11.738
2020-09-30 0.031 -10.166 -12.398
2020-06-30 0.07 -8.038 -10.703

NYMX Stock Price Chart Interactive Chart >

Price chart for NYMX

NYMX Price/Volume Stats

Current price $1.26 52-week high $2.27
Prev. close $1.25 52-week low $0.94
Day low $1.22 Volume 40,900
Day high $1.27 Avg. volume 178,734
50-day MA $1.36 Dividend yield N/A
200-day MA $1.60 Market Cap 113.75M

Nymox Pharmaceutical Corporation (NYMX) Company Bio


Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer’s disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company was founded in 1989 and is based in Nassau, The Bahamas.


NYMX Latest News Stream


Event/Time News Detail
Loading, please wait...

NYMX Latest Social Stream


Loading social stream, please wait...

View Full NYMX Social Stream

Latest NYMX News From Around the Web

Below are the latest news stories about Nymox Pharmaceutical Corp that investors may wish to consider to help them evaluate NYMX as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back to a new year, investor!

William White on InvestorPlace | January 3, 2022

What You Need To Know About Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) Investor Composition

A look at the shareholders of Nymox Pharmaceutical Corporation ( NASDAQ:NYMX ) can tell us which group is most...

Yahoo | January 3, 2022

Nymox Shareholder Update

HASBROUCK HEIGHTS, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the Company) is pleased to announce that it has completed all the Companys required tasks in preparation for its planned upcoming regulatory submission for Fexapotide Triflutate for the treatment of BPH.

Intrado Digital Media | December 13, 2021

State Street Corp Has $48,000 Position in Nymox Pharmaceutical Co. (NASDAQ:NYMX)

State Street Corp cut its position in Nymox Pharmaceutical Co. (NASDAQ:NYMX) by 95.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,494 shares of the biopharmaceutical companys stock after selling 624,899 shares during the period. State Street Corps holdings in Nymox Pharmaceutical were worth [] The post State Street Corp Has $48,000 Position in Nymox Pharmaceutical Co. (NASDAQ:NYMX) appeared first on ETF Daily News .

ETF Daily News | December 13, 2021

Head-To-Head Survey: Nymox Pharmaceutical (NYMX) vs. The Competition

Nymox Pharmaceutical (NASDAQ: NYMX) is one of 38 public companies in the Diagnostic substances industry, but how does it weigh in compared to its competitors? We will compare Nymox Pharmaceutical to related companies based on the strength of its valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and risk. Analyst Recommendations This is a summary []

Dakota Financial News | December 6, 2021

Read More 'NYMX' Stories Here

NYMX Price Returns

1-mo -10.64%
3-mo -8.70%
6-mo -13.70%
1-year -24.55%
3-year -25.00%
5-year -66.13%
YTD -3.08%
2021 -47.58%
2020 12.73%
2019 67.94%
2018 -60.30%
2017 23.60%

Continue Researching NYMX

Here are a few links from around the web to help you further your research on Nymox Pharmaceutical Corp's stock as an investment opportunity:

Nymox Pharmaceutical Corp (NYMX) Stock Price | Nasdaq
Nymox Pharmaceutical Corp (NYMX) Stock Quote, History and News - Yahoo Finance
Nymox Pharmaceutical Corp (NYMX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0331 seconds.